Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy

Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy

Novel Clinical Approaches in Multiple Myeloma: CAR T Cell Therapy

CAR T cell therapy is an effective strategy for patients with multiple myeloma. Tune in for the most recent data and applications for your patients.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Sagar Lonial, MD
    Chair and Professor, Department of Hematology and Medical Oncology
    Chief Medical Officer, Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, GA

    Research: BMS, Janssen, Novartis, Takeda
    Consulting Fees: AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Novartis,
    Other: Board of Directors with Stock, TG Therapeutics

    Noopur Raje, MD
    Clinical Director of the Center for Multiple Myeloma
    Massachusetts General Hospital
    Boston, MA

    Research: bluebird bio
    Consulting Fees: AbbVie, Amgen, BMS, Caribou Bioscience, Immuneel, Janssen, Novartis, Pfizer, Sanofi, Takeda

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Sara R. Fagerlie, PhD, CHCP, has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Discuss clinical data supporting the use of CAR T cell therapies in multiple myeloma
    2. Formulate practical approaches for CAR T cell therapy designed to achieve long-term success in patients with multiple myeloma
  • Target Audience

    This activity is designed to meet the educational needs of hematologist/oncologist MDs and other healthcare professionals who manage patients with hematologic malignancies

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free